Anand Rathi's research report on Dhanuka Agritech
Broadly in line with consensus and our estimates, Dhanuka Agritech reported a decent set of Q3 figures. Revenue/EBITDA/PAT grew 10%/22%/21% y/y. Key highlights: a) less pest infestation restricted revenue growth to 10% y/y in Q3 FY25, b) cheaper RM and a better product mix pushed up the gross margin 130bps y/y to 39.9%, c) innovation turnover index for 9M FY25 at 16.6% (15.3% a year ago), d) introduced one 9(4) product – “Roxa” – Pyroxasulfone 85% WG for the wheat crop, e) plans to launch eight 9(3) molecules in the next two years, f) acquired international rights of Iprovalicarb and Triadimenol from Bayer AG, aiming at global expansion, including manufacturing in India.
Outlook
Factoring in the 9M FY25 performance, management lowered its revenue growth guidance from 16% earlier to 14%, while it maintained the margin guidance of 100bp y/y improvement. We trim our FY25e 4% factoring in slower revenue growth, but broadly maintain our FY26e/27e. We maintain a Buy, with a revised TP of Rs1,850, 22x FY27e EPS (earlier Rs1,900).
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.